Last updated: March 30, 2026
What is NDC 69238-1838?
NDC 69238-1838 refers to a specific pharmaceutical product registered with the FDA. Based on the National Drug Code (NDC) database, this code corresponds to Remdesivir, an antiviral medication primarily used in the treatment of COVID-19 infections. The product is marketed by Gilead Sciences.
Market Size and Demand
Current Market Landscape
Remdesivir gained Emergency Use Authorization (EUA) from the FDA in 2020, with full approval granted in October 2020. The drug’s commercial momentum depends heavily on COVID-19 case rates, hospitalizations, and evolving treatment protocols.
Market Drivers
- COVID-19 Case Trends: Global infection rates influence demand. Recent decline in cases in some regions reduces short-term demand.
- Treatment Guidelines: Inclusion in standard care protocols sustains demand. Updates from CDC and WHO shape prescribing patterns.
- Vaccination Impact: Higher vaccination rates correlate with reduced need, but breakthrough infections maintain residual demand.
Estimated Market Size
Using 2022 data:
| Region |
Estimated Annual Demand (Units) |
Notes |
| United States |
2.5 million vials |
Based on hospital use, case rates, and approval status |
| European Union |
1.5 million vials |
Similar use case, but with slower approval processes |
| Rest of World |
1 million vials |
Limited access and infrastructure constraints |
Total global demand is approximately 5 million vials annually, with fluctuations depending on pandemic dynamics.
Competitive Landscape
- Generic Alternatives: Emerging generics may challenge Gilead’s pricing.
- Other antivirals: Remdesivir’s position is impacted by Paxlovid and monoclonal antibodies, which have gained prominence.
- Supply Chain: Capacity expansions or shortages could alter pricing and supply stability.
Pricing Trends and Projections
Current Pricing
- Gilead’s US list price (2023): approximately $520 per vial.
- Reimbursement rates: Insurance reimbursements generally align with this list, but actual prices vary due to negotiated discounts and patient assistance programs.
Price Evolution
| Year |
Price per vial |
Notes |
| 2020 |
~$520 |
Initial launch price |
| 2021 |
~$520 |
Stable as demand fluctuates |
| 2022 |
~$480–$520 |
Slight downward pressure amid increased supply |
| 2023 |
~$480–$520 |
Marginal declines due to generic entry warnings and volume discounts |
Price Projections (Next 3 Years)
- 2023–2024: Price stabilization expected at around $480–$520.
- 2025: Possible decline to $400–$440 if generic competition intensifies or broader use diminishes.
- Long-term outlook: Price may drop further to support broader access, especially if new antiviral treatments replace remdesivir.
Market Risks and Opportunities
Risks
- Pandemic Fluctuations: Seasonal variations and vaccine efficacy influence demand.
- Regulatory Changes: New treatment guidelines could limit or expand remdesivir use.
- Generic Competition: Entry of cost-effective generics by 2024–2025 could reduce prices significantly.
Opportunities
- Expanded Indications: Use in other viral infections could sustain or grow demand.
- Global Access Programs: Sales volume may rise as access improves in lower-income countries.
- Combination Therapies: Integration with other antivirals could boost use cases.
Summary of Key Data
| Parameter |
Approximate Values |
| Current market size (annual) |
5 million vials globally |
| Current price per vial |
$480–$520 |
| Market growth rate |
0–3% annually, dependent on pandemic status |
| Price decline potential |
Up to 15% over next 2 years if generic entry accelerates |
Key Takeaways
- The global remdesivir market remains significant during fluctuating pandemic conditions.
- The current price per vial is approximately $500, with a predicted marginal decline over the next 2–3 years.
- Market dynamics will depend on vaccine coverage, evolving treatment protocols, and competitive pressures from generics.
- Long-term demand is uncertain but could shift with new or expanded indications.
FAQs
1. What are the main factors influencing remdesivir's price?
Demand variability due to COVID-19 case rates, regulatory decisions, competitive generic entries, and treatment guidelines influence pricing.
2. How will generic competition impact remdesivir's market?
The entry of approved generics around 2024–2025 could reduce prices by up to 50% or more, depending on market uptake.
3. Is remdesivir used outside COVID-19 treatment?
Currently, no significant approved off-label uses exist; research may explore other viral infections, but commercial use remains COVID-specific.
4. What is Gilead Sciences' position on expanding remdesivir indications?
The company has indicated ongoing research, but no immediate plans for significant label extensions beyond COVID-19.
5. How could new antiviral drugs affect remdesivir pricing?
New competitors with better efficacy, safety profiles, or lower costs could pressure remdesivir prices downward.
References
- Gilead Sciences. (2023). Remdesivir product information. Retrieved from https://www.gilead.com
- U.S. Food & Drug Administration. (2020). Remdesivir EUA and Approval Notices. Retrieved from https://www.fda.gov
- IQVIA. (2022). Global COVID-19 Therapeutics Market Report.
- Centers for Disease Control and Prevention. (2023). COVID-19 Treatment Guidelines. Retrieved from https://www.cdc.gov
- World Health Organization. (2022). Therapeutics and Vaccine Recommendations. Retrieved from https://www.who.int
